Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses LBPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LBPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Lind | $610,000 | $0 | $0 | $986,934 | $442,860 | $0 | $14,010 | $2,053,804 |
| President and Chief Executive Officer | ||||||||
| Randall Kaye | 472,500 | 0 | 0 | 443,113 | 228,690 | 0 | 16,764 | 1,161,067 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Brandi Roberts | 436,800 | 0 | 0 | 362,547 | 211,411 | 0 | 14,442 | 1,025,200 |
| Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Kevin Lind | $2,053,804 | $1,505,915 | — | +547,889 |
| Randall Kaye | 1,161,067 | 1,385,828 | — | −224,761 |
| Brandi Roberts | 1,025,200 | 861,178 | — | +164,022 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Randall Kaye | Option | — | — | — | — | — | $443,113 |
| Kevin Lind | Option | — | — | — | — | — | 986,934 |
| Brandi Roberts | Option | — | — | — | — | — | 362,547 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Randall Kaye | $0 | $0 | $443,113 | 0.0% |
| Kevin Lind | 0 | 0 | 986,934 | 0.0% |
| Brandi Roberts | 0 | 0 | 362,547 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kevin Lind | Option | 257,965 | 4.35 | — |
| Brandi Roberts | Option | 37,749 | 8.56 | — |
| Kevin Lind | Option | 105,625 | 4.2 | — |
| Brandi Roberts | Option | 48,750 | 4.2 | — |
| Randall Kaye | Option | 115,821 | 4.35 | — |
| Brandi Roberts | Option | 94,763 | 4.35 | — |
| Randall Kaye | Option | 116,157 | 6 | — |
We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants, and directors, and encourages them to devote their best efforts to our business and financial success.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | — |
| Anti-pledging | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Paul J. SekhriIndependent · Board Chair · Compensation (Chair) | $86,992 | $0 | $58,815 | — | $0 | $145,807 |
| Phillip M. SchneiderIndependent · Audit (Chair) | 62,988 | 0 | 58,815 | — | 0 | 121,803 |
| Corinne Le GoffIndependent · Audit · Nominating and Corporate Governance | 55,996 | 0 | 58,815 | — | 0 | 114,811 |
| Casey C. LynchIndependent · Nominating and Corporate Governance (Chair) | 53,984 | 0 | 58,815 | — | 0 | 112,799 |
| Vincent E. AurentzIndependent · Audit · Compensation | 50,529 | 0 | 58,815 | — | 0 | 109,344 |
| Jane TillerIndependent · Compensation · Nominating and Corporate Governance | 49,512 | 0 | 58,815 | — | 0 | 108,327 |
| Kevin R. LindEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $58,815 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $360,001 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $360,001 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Longboard Pharmaceuticals | 2023 | Kevin Lind | $610,000 | $0 | $986,934 | $442,860 | $2,053,804 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Lind | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Summary Compensation Table”. As printed: 2,053,804. Filing ↗machine: r2 · c22 · span 476646–476655 |
| 2 | Section 01, Randall Kaye | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Summary Compensation Table”. As printed: 1,161,067. Filing ↗machine: r6 · c22 · span 500121–500130 |
| 3 | Section 01, Brandi Roberts | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Summary Compensation Table”. As printed: 1,025,200. Filing ↗machine: r4 · c22 · span 488375–488384 |
| 4 | Section 03, Randall Kaye Option | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t22 · r6 · c13 · span 497998–498005 |
| 5 | Section 03, Kevin Lind Option | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c13 · span 474523–474530 |
| 6 | Section 03, Brandi Roberts Option | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t22 · r4 · c13 · span 486252–486259 |
| 7 | Section 08, Paul J. Sekhri | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 145,807. Filing ↗machine: t27 · r6 · c11 · span 652178–652185 |
| 8 | Section 08, Phillip M. Schneider | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 121,803. Filing ↗machine: t27 · r5 · c11 · span 648886–648893 |
| 9 | Section 08, Corinne Le Goff | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 114,811. Filing ↗machine: t27 · r3 · c11 · span 642428–642435 |
| 10 | Section 08, Casey C. Lynch | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 112,799. Filing ↗machine: t27 · r4 · c11 · span 645654–645661 |
| 11 | Section 08, Vincent E. Aurentz | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 109,344. Filing ↗machine: t27 · r2 · c11 · span 639191–639198 |
| 12 | Section 08, Jane Tiller | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 108,327. Filing ↗machine: t27 · r7 · c11 · span 655484–655491 |
| 13 | Section 08, Kevin R. Lind | DEF 14A | 2024-04-12 | 0000950170-24-044023 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 16 | Section 09b board cost (computed) | Computed | — | computed | Cash 360,001 + equity 0 + all other 0 = 360,001, summed across the director compensation table rows.machine: formula: Σ = 360,001 |
| 17 | Longboard Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044023 | CEO total compensation as printed in Longboard Pharmaceuticals's own proxy. As printed: 2,053,804. Filing ↗machine: r2 · c22 · span 476646–476655 |